近年来,ADC(抗体偶联药物)市场正高速增长。根据Frost & Sullivan(沙利文)的预测,全球ADC市场2032年预计将达到1151亿美元,2023-2032年复合年增长率(CAGR)为30.6%。值得注意的是,在市场规模不断扩大的同时,药企在该领域的布局也正不断加速。1月14日,药明合联抛出一份99%溢价的现金要约收购方案,其拟以高达27.9亿港元的代价收购东曜药业。据公告,该要约总...
Source Link近年来,ADC(抗体偶联药物)市场正高速增长。根据Frost & Sullivan(沙利文)的预测,全球ADC市场2032年预计将达到1151亿美元,2023-2032年复合年增长率(CAGR)为30.6%。值得注意的是,在市场规模不断扩大的同时,药企在该领域的布局也正不断加速。1月14日,药明合联抛出一份99%溢价的现金要约收购方案,其拟以高达27.9亿港元的代价收购东曜药业。据公告,该要约总...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.